ZVRA — Zevra Therapeutics, Inc.

Zevra (ZVRA) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $34.1 million, with $26.4 million from MIPLYFFA sales.
• Full Year 2025 Revenue: $106.5 million, driven by MIPLYFFA ($87.4 million).
• Net Income: Q4 net income of $12.2 million ($0.20 per basic share), compared to a net loss of $35.7 million in Q4 2024.
• Full Year Net Income: $83.2 million ($1.40 per basic share), a significant improvement from a net loss of $105.5 million in 2024.
• Operating Expenses: Q4 operating expenses were $23 million, a decrease of $1.5 million year-over-year. Full year operating expenses totaled $90.4 million, down $6.6 million from 2024.
• Cash Position: As of December 31, 2025, cash, cash equivalents, and investments totaled $238.9 million, with total debt at approximately $61.9 million.

2. Strategic Updates and Business Highlights

• MIPLYFFA Performance: Strong commercial performance with 52 prescription enrollment forms in 2025 and 24 in Q4. Total enrollments since launch reached 161.
• Market Expansion: MIPLYFFA has exclusivity in the U.S. until 2031, with a patent term extension under review. The company is expanding access through a global expanded access program (EAP) with 113 patients enrolled by year-end.
• Regulatory Progress: Submitted a marketing authorization application to the European Medicines Agency (EMA) and is preparing responses to a 120-day list of questions from regulators.
• Pipeline Development: Advancing Celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) with ongoing Phase III DISCOVER study, currently enrolling patients.

3. Forward Guidance and Outlook

• Growth Drivers: Anticipated continued growth in MIPLYFFA sales driven by increased patient identification and education efforts. The company is optimistic about expanding its patient base and market penetration.
• 2026 Expectations: While the company expects variability in quarterly sales due to the nature of ultra-rare diseases, there is confidence in the potential to reach a larger segment of the diagnosed patient population (estimated between 300-900 patients).

4. Bad News, Challenges, or Points of Concern

• Enrollment Variability: The company acknowledged that patient enrollment and sales may fluctuate due to the low number of patients in the ultra-rare disease space.
• Competitive Pressures: Potential competition from other treatments, such as Mandos' adrabetadex for infantile onset NPC, could impact MIPLYFFA's market position. However, management believes MIPLYFFA remains the preferred disease-modifying treatment.
• Regulatory Risks: The company must navigate the regulatory landscape effectively, particularly with the EMA's review process and the potential for additional data requests.

5. Notable Q&A Insights

• Patient Identification: Management highlighted the effectiveness of their disease awareness campaigns and AI-driven targeting models in identifying newly diagnosed patients, which is crucial for future growth.
• Persistency Data: While it is too early to provide specific data on patient persistency on MIPLYFFA, refill rates are encouraging, suggesting strong adherence to therapy.
• Global EAP Insights: The EAP is expected to show variability in revenue as it expands beyond Europe, with initial shipments indicating a positive start.
• Market Dynamics: Management emphasized the importance of collaboration with genetic testing companies to expedite patient diagnoses and the overall positive impact of increased awareness on the treatment landscape.

Overall, Zevra reported a strong quarter and year, with significant improvements in financial performance and strategic initiatives aimed at expanding patient access and enhancing their product pipeline. However, they face challenges related to market competition and the inherent variability of patient enrollment in ultra-rare diseases.